newsfilter
← Latest News
GlobeNewswire·

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected